NEW YORK--(BUSINESS WIRE)--Neuro-Hitech, Inc. (NASDAQ: NHPI - News), a biopharmaceutical company focused on the development and commercialization of next-generation compounds for neurodegenerative diseases, today announced that Alan Kestenbaum, a director and founder of the company, established a pre-arranged stock trading plan, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Rule 10b5-1 permits individuals who are not in possession of material, non-public information at the time the plan is adopted to establish pre-arranged plans to buy or sell company stock. Using these plans, individuals can prudently and gradually diversify their investment portfolios over an extended period of time.
